Topics

Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. Company Profile

13:49 EDT 21st September 2019 | BioPortfolio

Founded in 2000, Cambrooke is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious, chronic, unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooke.com.


News Articles [921 Associated News Articles listed on BioPortfolio]

Cambrooke Therapeutics, Inc. Becomes Ajinomoto Cambrooke, Inc.

Cambrooke Therapeutics, Inc. announced it has changed its corporate name to Ajinomoto Cambrooke, Inc. effective April 1, 2019. In November 2017, Cambrooke became part of ...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

Ajinomoto Appoints VP of Sales & Marketing

Jean-Baptiste Agnus joins Ajinomoto Bio-Pharma Services from Novasep

Ajinomoto acquires JV to integrate its CDMO business

Ajinomoto to acquire remaining interest of its small molecule and API manufacturing joint venture from Granules India.

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India

Ajinomoto Buys Out Granules India From JV

Ajinomoto Bio-Pharma Services has announced it is buying out partner Granules India from an API manufacturing joint-venture based in southern India as...   

GeneDesign Joins Ajinomoto Bio-Pharma Services

Opens oligonucleotide API development center

Ajinomoto Bio-Pharma Services Expands

Invests more than $100 million to further expand offerings and capabilities in both the U.S. and Belgium

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [444 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Glycan analysis for protein therapeutics.

Glycosylation can be a critical quality attribute for protein therapeutics due to its extensive impact on product safety and efficacy. Glycan characterization is important in the process of protein dr...

Clinical Trials [187 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1380 Associated Companies listed on BioPortfolio]

Cambrooke Therapeutics Inc.

Founded in 2000, Cambrooke Therapeutics, a proud member of The Ajinomoto Group, is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition pro...

Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc.

Founded in 2000, Cambrooke is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious, chronic, unmet medic...

Ajinomoto Cambrooke, Inc.

Ajinomoto Health & Nutrition North America, Inc. is a wholly-owned subsidiary of Ajinomoto Co., Inc., a global leader in the research, development, manufacture and sale of amino a...

Ajinomoto Co. (H.K.) Ltd

Ajinomoto Co.Inc, is a global corporation in Food and Amino Acid Products. With headquarters in Japan, AJINOMOTO has operations over 23 countries and regions, including 108 manufacturing plants in 15 ...

Ajinomoto Co., Inc.

Ajinomoto is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto has con...

More Information about "Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc." on BioPortfolio

We have published hundreds of Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. news stories on BioPortfolio along with dozens of Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. Clinical Trials and PubMed Articles about Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. Companies in our database. You can also find out about relevant Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...


Corporate Database Quicklinks



Searches Linking to this Company Record